Categorical variables were reported using frequencies and percentages and analyzed using chi-squared tests where appropriate
Regulatory Compliance & Acceptance GLP Certification meets OECD, FDA, MHRA, EMA, and national regulatory expectations
the 20% threshold was not part of the statistical testing hierarchy) Among the participants for whom data were available at the week 68 visit (1212 participants in the semaglutide group and 577 in the placebo group), these thresholds were reached by 86.4% (1047 participants), 69.1% (838 participants), 50.5% (612 participants), and 32.0% (388 participants), respectively, in the semaglutide group, as compared with 31.5% (182 participants), 12.0% (69 participants), 4.9% (28 participants) Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo
Learn More AutoShip Price: $13.49 $0.13 / count First shipment within 1 business day with FREE standard shipping
Your provider will use your lipid panel results, along with other factors, to get a complete picture of your heart health
Semaglutide, injected once a week with a small needle, offers an appetite-suppressing effect without any pain or bleeding
